Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model. [electronic resource]
Producer: 20150109Description: 138-44 p. digitalISSN:- 1556-9535
- Administration, Topical
- Angiogenesis Inhibitors -- administration & dosage
- Animals
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antigens, CD34 -- metabolism
- Cornea -- drug effects
- Corneal Neovascularization -- drug therapy
- Male
- Ranibizumab
- Rats, Sprague-Dawley
- von Willebrand Factor -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.